Surrozen, Inc./DE

Churchill Capital Corp VII, trading under the ticker CHFW and sponsored by Churchill Capital, filed an 8-K with the SEC on August 6, 2026, with the registrant listed as Surrozen, Inc., a Delaware corporation operating in the biopharmaceutical sector. The filing reflects the SPAC's de-SPAC business combination with Surrozen, a clinical-stage biotechnology company focused on Wnt signaling pathway therapeutics for organ regeneration and repair. Churchill Capital Corp VII completed its initial public offering in 2021, targeting healthcare and life sciences acquisition targets. The combined entity now operates under Surrozen's name, marking the transition from blank-check company to operating public issuer. Visit SpacDesk and sign up for full data, filings history, and deal analytics on CHFW and hundreds of other SPAC transactions.